Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1Classical hematology 1CNS 1Breast 1

Conditions

Fanconi Anemia 1

Interventions

Cyclophosphamide 37fludarabine phosphate 35Mycophenolic Acid 33Whole-Body Irradiation 32Busulfan 24Tacrolimus 22fludarabine 21Peripheral Blood Stem Cell Transplantation 20Cyclosporine 20Melphalan 17Antilymphocyte Serum 13Methotrexate 12Filgrastim 12Granulocyte Colony-Stimulating Factor 11Cytarabine 11Cord Blood Stem Cell Transplantation 11Thiotepa 9thymoglobulin 8eltrombopag 8Lenalidomide 7Etoposide 7Epoetin Alfa 7Dalteparin 7romiplostim 6Darbepoetin alfa 6Alemtuzumab 6merphos 5apixaban 5Sirolimus 5Radiotherapy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × prexasertib × Classical hematology × Clear all
NCT02873975 2022-10-21

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Dana-Farber Cancer Institute

Phase 2 Completed
27 enrolled 13 charts
Classical hematology

Fanconi Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡